PMVP earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -0.89. Updated 2026-07-23.
PMV Pharmaceuticals (PMVP) Research Hub
PMV Pharmaceuticals (PMVP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.4 USD (+1.45%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.89, market cap 0.07B. This hub links to the full technical, earnings and options research available for PMVP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.4 USD (+1.45%) |
| 52-week range | 1.05 USD – 1.505 USD |
| Trend regime | Range |
| 14-day RSI | 65.2 (Bullish) |
| Trailing P/E | -0.89 |
| Market cap | 0.07B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for PMVP
Covered Call on PMVP: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PMVP: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PMVP: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
PMVP technical analysis: range, last 1.4 USD, RSI 65.2, 52w range 1.05 USD–1.505 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PMVP in?
PMV Pharmaceuticals (PMVP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PMVP in an uptrend or downtrend?
As of 2026-09-11, PMVP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PMVP's trailing P/E ratio?
PMVP's trailing P/E is -0.89, with a market cap of 0.07B. See the earnings research page for full valuation detail.
When does PMVP next report earnings?
PMVP is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.38 USD.